August 1st, 2024, Hong Kong, China - Hong Kong WinHealth Pharma Group Co. Limited（”WinHealth Pharma”） announced that it has signed a stock purchase agreement with Kyowa Kirin Co., Ltd. on August 1, 2024, under which WinHealth will acquire 100% of the shares of its subsidiary - Kyowa Kirin China Pharmaceutical Co., Ltd. ("Kyowa Kirin China").
The scope of the transaction includes the transfer of all rights and interests of Kyowa Kirin China, and WinHealth will obtain the perpetual commercialization and manufacturing rights of five Original branded drugs that are listed or commercially available in China through this acquisition. In addition, WinHealth Pharma has also signed a license agreement with Kyowa Kirin for Global products Crysvita® and Poteligeo®, obtaining their commercialization rights in China.
Chairman of Hong Kong WinHealth Pharma Group, Jack Wang said: "Patient-First has always been our core philosophy. The successful acquisition of Kyowa Kirin China will be a key milestone in our company's development, marking the beginning of a new chapter for the company. We will continue to provide high-quality drugs for patients and continuously expand our product portfolio by cooperating with the world's leading pharmaceutical and biotechnology companies to meet more unmet medical needs. This transaction not only enhances our R&D and commercialization capabilities but also further consolidates our market position in the Asia-Pacific region. We believe that through such efforts, WinHealth Pharma will achieve sustainable development and bring good news to more patients.
Hong Kong WinHealth Pharma Group Executive Director and Co-CEO Oliver HAO said: "This acquisition is a natural evolution and rational outcome of the deep cooperation between Kyowa Kirin China and WinHealth over the past eight years. We will continue to fulfill WinHealth's commitment to patients, partners, and employees, an d strive to introduce more innovative therapies for kidney disease, hematological tumors, and rare diseases into China to help patients to regain their smiles.
We believe that through this acquisition, WinHealth Pharma will occupy a more advantageous position in the market, further enhancing the company's industry competitiveness and market share. In the future, we will gradually improve the layout of the entire industry chain, combine our own development advantages and profound understanding of the industry, and always adhere to the original intention of the enterprise centered on patients, to bring more treatment opportunities to patients around the world.
For more information, please refer to:
https://www.kyowakirin.com/media_center/news_releases/2024/pdf/e20240801_02.pdf
https://www.kyowakirin.com/asiapacific/media/2024/08/new_sustainable_business_strategy_press_release_kkap.pdf
About Hong Kong Winhealth Pharma Group
Hong Kong Winhealth Pharma Group is a leading biopharmaceutical company based in Hong Kong, with commercial operations across the Greater China Area and an expanding regional footprint in Asia and Europe. Specializing in the commercialization of innovative medicines, the company is dedicated to delivering breakthrough therapies for patients with cardio-renal, gastrointestinal, respiratory and anti-infectious and rare diseases, as well as other unmet and severely underserved medical needs.
WinHealth has established successful long-term partnerships with numerous world-leading pharmaceutical and biotechnology companies, creating a uniquely impactful and diversified portfolio that includes over 15 specialty products in both commercial and late clinical stages. Committed to patients and partners, WinHealth continuously expands its portfolio and seeks to bring more transformative therapies from its global network of partners.
For more information, please visit www.winhealth.hk.
About Kyowa Kirin
Kyowa Kirin aims to discover novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, we have invested in drug discovery and biotechnology innovation for more than 70 years and are currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients affected by a severe or rare disease. A shared commitment to our values, to sustainable growth, and to making people smile unites us across our four regions – Japan, Asia Pacific, North America, and EMEA/International. You can learn more about the business of Kyowa Kirin at www.kyowakirin.com.